AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 81 min read$UTHR

ROTHBLATT MARTINE A sold $4.6M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $489.20 ($485.85–$491.69, $4.65M total) across 7 trades on 2026-09-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Sep 8, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Neutral
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRNeutralLow
01

Why it matters

The disclosed sale is a primary source event; while sizable, it follows a pre‑arranged 10b5‑1 plan, limiting its predictive power.

02

Market read

First‑report insider sale; modest materiality; may cause short‑term price adjustment.

03

What to watch

Potential upcoming clinical trial results or partnership announcements could offset any negative sentiment from the sale.

Relevance 5/10Novelty 5/10Timing: after market close on 2026‑09‑04

Background

Form 4 filing discloses insider transactions required by the SEC, providing transparent ownership changes.

Company-level read

Ticker impact

$UTHRNeutralMedium confidence
Context

CEO Martine A. Rothblatt sold 9,500 shares for $4.65M via a 10b5‑1 plan, reducing her stake to 324,443 shares.

Expected impact

Potential modest dip of 1‑2% in the near term as the market digests the sale.

Evidence & confidence

A $4.6M sale by the chairperson is material but executed under a pre‑arranged plan, limiting informational content.

Market effects

Sector

Biotech/therapeutics sector may see slight caution as insider activity is monitored.

Regional

Limited to U.S. markets where United Therapeutics trades.

Global

Minimal global impact; primarily relevant to UTHR shareholders.

Counterpoint

What could challenge this read

The sale could be purely liquidity‑driven; the stock may remain stable or rebound if fundamentals stay strong.

Key entities

  • Company
    United Therapeutics Corp

    Biopharmaceutical company developing therapies for pulmonary arterial hypertension and other diseases.

  • Executive
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min